Johnson & Johnson (NYSE:JNJ) is among the most profitable healthcare stocks to buy. On January 22, TD Cowen lifted the price target on Johnson & Johnson (NYSE:JNJ) to $250, up from$222, and maintained a Buy rating, citing the company’s fourth quarter results. The revised price target reflects an upside potential of approximately 14%. According to the firm, the initial projection of Johnson & Johnson (NYSE:JNJ) should uplift the consensus revenue and EPS forecasts for the healthcare powerhouse. From this ...